Infergen(interferon alfacon-1)
Infergen (interferon alfacon-1) is a protein pharmaceutical. Interferon alfacon-1 was first approved as Infergen on 1997-10-06. It is used to treat brain neoplasms, chronic hepatitis c, colorectal neoplasms, cryoglobulinemia, and essential thrombocythemia amongst others in the USA. It has been approved in Europe to treat chronic hepatitis c.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| neoplasms | D009369 |
| digestive system diseases | D004066 |
| nervous system diseases | D009422 |
| eye diseases | D005128 |
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| hemic and lymphatic diseases | D006425 |
| skin and connective tissue diseases | D017437 |
| immune system diseases | D007154 |
Show 1 more
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Interferon alfacon-1
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Infergen | interferon alfacon-1 | Sanofi | N-103663 DISCN | 1997-10-06 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| brain neoplasms | EFO_0003833 | D001932 | C71 |
| chronic hepatitis c | EFO_0004220 | D019698 | B18.2 |
| colorectal neoplasms | — | D015179 | — |
| cryoglobulinemia | EFO_0005846 | D003449 | D89.1 |
| essential thrombocythemia | — | D013920 | D47.3 |
| hairy cell leukemia | — | D007943 | C91.4 |
| hemangioma | — | D006391 | D18.0 |
| hepatitis d | EFO_0007304 | D003699 | — |
| hepatocellular carcinoma | — | D006528 | C22.0 |
| hypereosinophilic syndrome | EFO_1001467 | D017681 | D72.11 |
Show 12 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9212 | Injection, interferon alfacon-1, recombinant, 1 microgram |
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 1 | 3 | — | — | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Human influenza | D007251 | EFO_0007328 | J11.1 | 1 | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | INTERFERON ALFACON-1 |
| INN | interferon alfacon-1 |
| Description | Interferon alpha-2 precursor (Interferon alpha-A) (LeIF A) |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 118390-30-0 |
| RxCUI | 59744 |
| ChEMBL ID | CHEMBL1201557 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00069 |
| UNII ID | 56588OP40D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 123 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,000 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more